Template:Quinapril: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) No edit summary |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{CMG}}; {{AE}} {{AZ}}, {{AM}} | {{CMG}}; {{AE}} {{AZ}}, {{AM}} | ||
'''''For patient information about Quinapril, click [[Quinapril (patient information)|here]].''''' | |||
===''Quinapril''=== | ===''Quinapril''=== | ||
Latest revision as of 19:49, 22 April 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2], Amr Marawan, M.D. [3]
For patient information about Quinapril, click here.
Quinapril
Quinapril and Hydrochlorothiazide tablet
Overview
Quinapril tablet is an angiontensin converting enzyme inhibitor drug that is FDA approved for the treatment of hypertension, heart failure, left ventricular dysfunction after myocardial infarction, diabetic nephropathy. Adverse reactions include hypotension, rash, hyperkalemia, disorder of taste, cough. hypotension, rash, hyperkalemia, disorder of taste, cough.
Category
Antihypertensive Agents, Angiotensin Converting Enzyme Inhibitors.